Do you want to read an article? Please log in or register.
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Atrial FibrillationTherapy and Intervention
Related content
Atrial FibrillationThrombosis and StrokeTherapy and Intervention
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
J Am Heart Assoc.
Martinez BK, Sood NA, Bunz TJ, Coleman CI
doi: 10.1161/JAHA.118.008643.
Atrial FibrillationTherapy and Intervention
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial
Circ Cardiovasc Interv.
Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP
doi: 10.1161/CIRCINTERVENTIONS.119.008349.
Atrial Fibrillation
Assessment of Atrial Fibrillation–Specific Symptoms Before and 2 Years After Atrial Fibrillation Ablation
JACC: Clinical Electrophysiology
Björkenheim A, Brandes A, Magnuson A, Chemnitz A, Svedberg L, Edvardsson N, Poçi D
doi: 10.1016/j.jacep.2017.04.003.
Atrial Fibrillation
Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies
J Am Heart Assoc.
Brouwer TF, Whang W, Kuroki K, Halperin JL, Reddy VY
doi: 10.1161/JAHA.119.013525.
COMMENTED
Atrial Fibrillation
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial
★ 3
Recommended and commented by
Prof. Dr Sacha P. Salzberg, Faculty Member
doi: 10.1001/jama.2019.21187.
Atrial Fibrillation
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
Clin Res Cardiol.
Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH
doi: 10.1007/s00392-019-01594-9.
Atrial FibrillationHeart, Artery and Coronary DiseasesVentricular Function
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study
J Am Coll Cardiol.
Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, Sugumar H, Lockwood SM, Stokes MB, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Gutman SJ, Lee G, Layland J, Mariani JA, Ling LH, Kalman JM, Kistler PM
doi: 10.1016/
Thrombosis and Stroke
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Eur Heart J.
Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L, Morillo CA, Abozguia K, Grimaldi M, Rauer H, Reimitz PE, Smolnik R, Mönninghoff C, Kautzner J
doi: 10.1093/eurheartj/
Atrial Fibrillation
Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Am Heart J.
Jackson LR 2nd, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
doi: 10.1016/j.ahj.2020.04.016.